Cardiology Letters 2012, 21(5):420-427

Pharmacotherapy aimed at reducing LDL-Cholesterol. Statins, combined hypolipidemic therapy and what next?

Fábryová Ľ

Metabol KLINIK s.r.o., Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, Špecializovaná lipidologická ambulancia, MED PED centrum v Bratislave, Slovenská republika

Strategies for preventing complications of atherosclerotic vascular disease have emphasized risk factor modification using treatment approaches supported by evidence-based medicine (aspirin and/or clopidogrel, β-adrenergic blockers, angiotensin-converting enzyme inhibitors and statins). Despite the intensive management conventional risk factors (also with higher doses of statins or combined hypolipidemic therapy) residual cardiovascular and cerebrovascular risks remain high. There is the prospect that developing novel hypolipidemic therapies that target the atherogenic lipoproteins - squalene synthase inhibitors, microsomal transfer protein inhibitors, antisense oligonucleotides to apo B, anti PCSK9 monoclonal antibodies will provide incremental benefit for the high risk cardiovascular disease patient. In Slovakia there are ongoing or planned clinical studies with these new classes of lipid-lowering agents, which for many of us means important clinical experience. Fig 4, Ref. 31 Online full text (Free, PDF)

Keywords: squalene synthase inhibitors; MTP inhibitors; antisense oligonucleotides to apo B; anti PCSK9 monoclonal antibodies

Published: May 1, 2012  Show citation